CIK: 0001536562 · Show all filings
Period: Q2 2017 (← Previous) (Next →)
Filing Date: Aug 4, 2017
Total Value ($000): $75,397 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | POWERSHARES QQQ TRUST SERIES 1 | 180,000 | $24,775 | 32.9% | — | — | Put | 73935A104 |
| SPY | SPDR S&P 500 ETF TRUST | 100,000 | $24,180 | 32.1% | — | — | Put | 78462F103 |
| EEM | ISHARES MSCI EMERGING MARKETS ETF | 350,000 | $14,487 | 19.2% | — | — | Put | 464287234 |
| INCY | INCYTE CORP | 23,300 | $2,934 | 3.9% | $105.86 | +20.2% | COMMON STOCK | 45337C102 |
| BMRN | BIOMARIN PHARMACEUTICALS INC | 19,264 | $1,750 | 2.3% | $85.05 | +7.0% | COMMON STOCK | 09061G101 |
| — | CELGENE CORP | 11,333 | $1,472 | 2.0% | $99.79 | — | COMMON STOCK | 151020104 |
| UNH | UNITEDHEALTH GROUP INC | 7,850 | $1,456 | 1.9% | $121.60 | +25.6% | COMMON STOCK | 91324P102 |
| — | ALEXION PHARMACEUTICALS IN | 10,743 | $1,307 | 1.7% | $145.42 | — | COMMON STOCK | 015351109 |
| — | SEATTLE GENETICS INC | 19,634 | $1,016 | 1.3% | $52.15 | — | COMMON STOCK | 812578102 |
| LLY | LILLY ELI & CO | 6,426 | $529 | 0.7% | $63.99 | +11.4% | COMMON STOCK | 532457108 |
| REGN | REGENERON PHARMACEUTICALS | 961 | $472 | 0.6% | $398.98 | +9.1% | COMMON STOCK | 75886F107 |
| VRTX | VERTEX PHARMACEUTICALS INC | 2,697 | $348 | 0.5% | $89.66 | +34.3% | COMMON STOCK | 92532F100 |
| — | TESARIO INC | 2,294 | $321 | 0.4% | $142.07 | — | COMMON STOCK | 881569107 |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5,890 | $271 | 0.4% | $44.87 | +8.1% | COMMON STOCK | 64125C109 |
| EWZ | ISHARES MSCI BRAZIL CAPPED IND | 2,300 | $79 | 0.1% | — | — | Call | 464286400 |